Does MEPOLIZUMAB Cause Interstitial lung disease? 68 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Interstitial lung disease have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.2% of all adverse event reports for MEPOLIZUMAB.
68
Reports of Interstitial lung disease with MEPOLIZUMAB
0.2%
of all MEPOLIZUMAB reports
10
Deaths
33
Hospitalizations
How Dangerous Is Interstitial lung disease From MEPOLIZUMAB?
Of the 68 reports, 10 (14.7%) resulted in death, 33 (48.5%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does MEPOLIZUMAB Cause?
Asthma (11,033)
Dyspnoea (9,192)
Wheezing (6,093)
Product dose omission issue (5,873)
Cough (4,577)
Pneumonia (4,107)
Therapeutic product effect incomplete (4,106)
Drug ineffective (3,880)
Loss of personal independence in daily activities (3,566)
Fatigue (2,656)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which MEPOLIZUMAB Alternatives Have Lower Interstitial lung disease Risk?
MEPOLIZUMAB vs MEPROBAMATE
MEPOLIZUMAB vs MERCAPTOPURINE
MEPOLIZUMAB vs MEROPENEM
MEPOLIZUMAB vs MEROPENEM ANHYDROUS
MEPOLIZUMAB vs MESALAMINE